<DOC>
	<DOCNO>NCT00269841</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety anti-TNF chimeric monoclonal antibody ( cA2 ) compare placebo treatment patient fistulizing Crohn 's disease .</brief_summary>
	<brief_title>An Efficacy Safety Study Anti-TNF Monoclonal Antibody Patients With Fistulizing Crohn 's Disease</brief_title>
	<detailed_description>This randomize , placebo-controlled , double-blind , repeated-dose study evaluate effectiveness safety anti-TNF chimeric monoclonal antibody ( cA2 ) compare placebo treatment patient fistulizing Crohn 's disease . The primary efficacy outcome study number patient least 50 % reduction baseline number open fistula observe least two consecutive evaluation visit . Patients treat either anti-TNF chimeric monoclonal antibody ( cA2 ) match placebo .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients Crohn 's disease least 3 month duration confirm radiography orendoscopy Having single multiple drain enterocutaneous ( include perianal ) fistulae least 3 month duration If treat oral prednisone ( equivalent ) , dose must &lt; =40 mg/day must stable least 3 week prior enrollment . ( If currently treat oral prednisone , stop date must least 4 week prior enrollment ) If treat 6mercaptopurine azathioprine , start date must least 6 month prior enrollment . ( The dose must stable least 8 week prior enrollment . If currently treat 6mercaptopurine azathioprine , stop date must least 4 week prior enrollment . ) Patients local complication Crohn 's disease strictures abscess might confound evaluation benefit cA2 treatment Having abscess drain prior enrollment , least 3 week drainage abscess enrollment Having serious infection , hepatitis , pneumonia pyelonephritis , previous 3 month history opportunistic infection herpes zoster within 2 month prior screen , evidence active cytomegalovirus , active pneumocystis carinii , drug resistant atypical mycobacterium Currently sign symptom severe , progressive uncontrolled renal , hepatic , hematologic , endocrine , pulmonary , cardiac , neurologic cerebral disease Currently know malignancy history malignancy within past 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>fistula</keyword>
	<keyword>Crohn 's Disease</keyword>
</DOC>